Merrion Pharmaceuticals, LLC (Merrion)

Oncology Corporate Profile

HQ Location

P. O. Box 3407
Wilmington, NC 28406

Company Description

Merrion Pharmaceuticals is a publicly listed specialty pharmaceutical company engaged in the development of oral forms (tablets/capsules) of drugs that have poor absorption and are generally given by injection. Merrion was established in 2003 to commercialise various technologies acquired from Elan Corporation, plc. Merrion's patented drug delivery technologies increase bioavailability, by improving absorption in the gastrointestinal tract, of drugs that are otherwise poorly absorbed.

Website: http://www.merrionpharma.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Orazol® / MER-101bisphosphonate (oral)Adjuvant Breast cancerIII
Orazol® / MER-101bisphosphonate (oral)Bone metastases associated with Hormone refractory Prostate cancer (HRPC)II
acyline / MER-104GnRH antagonist (oral)Prostate cancerI

View additional information on product candidates here »

Source: http://www.merrionpharma.com/

Recent News Headlines

There are no news items to display